<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35891179</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>24</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>The Frequency and Patterns of Post-COVID-19 Vaccination Syndrome Reveal Initially Mild and Potentially Immunocytopenic Signs in Primarily Young Saudi Women.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1015</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines10071015</ELocationID><Abstract><AbstractText>Vaccination is the most promising approach for ending or containing the SARS-CoV-2 pandemic. However, serious post-COVID-19 vaccine reactions, including immunocytopenia (ITP) syndrome, have been increasingly reported. Several factors cause increased risks including multiple doses, age-dependent heterogeneity in immune-responses, platelet cross-reactions with microbial components, and Long-COVID syndrome. Thus, in the absence of widely available specific therapeutics, vigilance is important while more studies are needed. Using a structured questionnaire sent to different regions in Saudi Arabia, we conducted a comprehensive investigation on the frequency, rates, disease patterns, and patient demographics of post-COVID-19 vaccine side effects on febrile patients after administration three major vaccines. Results indicated that the majority of respondents administered Pfizer BioNtech vaccine (81%, <i>n</i> = 809); followed by AstraZeneca (16%, <i>n</i> = 155); and Moderna (3%, <i>n</i> = 34). Overall 998 participants, 74% (<i>n</i> = 737) showed no serious symptoms; however, 26.2% (<i>n</i> = 261) revealed typical syndromes. In a focused group of 722 participants, the following rates were identified: shortness of breath (20%), bruises or bleeding (18%), inattention (18%), GIT symptoms (17.6%), skin irritation (8.6%), and anosmia and ageusia (8%) were the most prominent among those who showed typical symptoms. The onset time was mostly between 1-3 days in 49% (<i>n</i> = 128), followed by 4-7 days in 21.8% (<i>n</i> = 57), 8-14 days in 16.5% (<i>n</i> = 43), and more than a month in 12.6% (<i>n</i> = 33). The onsets occurred mostly after the first, second, or both doses, 9%, 10%, and 7% of participants, respectively. The frequency of symptoms was significantly higher after Moderna<sup>&#xae;</sup> vaccine (<i>p</i>-value = 0.00006) and it was significantly lower in participants who received Pfizer (<i>p</i>-value = 0.00231). We did not find significant difference in symptoms related to differences in regions. Similarly, the region, age, sex, education, and nationality had no influence on the dose and onset timings. The findings of this study have significant clinical implications in disease management strategies, preventive measures, and vaccine development. Future vertical studies would reveal more insights into the mechanisms of post-COVID-19 vaccine syndrome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Said</LastName><ForeName>Kamaleldin B</ForeName><Initials>KB</Initials><Identifier Source="ORCID">0000-0002-3749-6754</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Microbiology, College of Medicine, University of Ha'il, Ha'il 55476, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genomics, Bioinformatics and Systems Biology, Carleton University, 1125 Colonel-By Drive, Ottawa, ON K1S 5B6, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ASC Molecular Bacteriology, McGill University, 21111 Lakeshore Rd., Montreal, QC H9X 3L9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Otaibi</LastName><ForeName>Amal</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology and Microbiology, College of Medicine, University of Ha'il, Ha'il 55476, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aljaloud</LastName><ForeName>Luluh</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology and Microbiology, College of Medicine, University of Ha'il, Ha'il 55476, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Anazi</LastName><ForeName>Basmah</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology and Microbiology, College of Medicine, University of Ha'il, Ha'il 55476, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alsolami</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, College of Medicine, University of Ha'il, Ha'il 55476, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alreshidi</LastName><ForeName>Fayez Saud</ForeName><Initials>FS</Initials><Identifier Source="ORCID">0000-0002-2391-9090</Identifier><AffiliationInfo><Affiliation>Deparmtent of Family, Community Medicine, College of Medicine, University of Ha'il, Ha'il 55476, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>On Behalf Of The Ha'il Com Research Unit Group</LastName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RG20064</GrantID><Agency>University of Hail</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 reactions</Keyword><Keyword MajorTopicYN="N">COVID-vaccine women susceptibility</Keyword><Keyword MajorTopicYN="N">ITP syndromes 2</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35891179</ArticleId><ArticleId IdType="pmc">PMC9323608</ArticleId><ArticleId IdType="doi">10.3390/vaccines10071015</ArticleId><ArticleId IdType="pii">vaccines10071015</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Saudagar V., Patil S., Goh S., Pothiawala S. Vigilance Regarding Immune Thrombocytopenic Purpura after COVID-19 Vaccine. Ir. J. Med. Sci. 2022;191:919. doi: 10.1007/s11845-021-02614-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11845-021-02614-2</ArticleId><ArticleId IdType="pmc">PMC8011062</ArticleId><ArticleId IdType="pubmed">33788135</ArticleId></ArticleIdList></Reference><Reference><Citation>Favaloro E.J. Laboratory Testing for Suspected COVID-19 Vaccine&#x2013;Induced (Immune) Thrombotic Thrombocytopenia. Int. J. Lab. Hematol. 2021;43:559&#x2013;570. doi: 10.1111/ijlh.13629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijlh.13629</ArticleId><ArticleId IdType="pmc">PMC8444734</ArticleId><ArticleId IdType="pubmed">34138513</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawed M., Khalid A., Rubin M., Shafiq R., Cemalovic N. Acute Immune Thrombocytopenia (ITP) Following COVID-19 Vaccination in a Patient with Previously Stable ITP. Open Forum. Infect. Dis. 2021;8:ofab343. doi: 10.1093/ofid/ofab343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab343</ArticleId><ArticleId IdType="pmc">PMC8294682</ArticleId><ArticleId IdType="pubmed">34307734</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharifian-Dorche M., Bahmanyar M., Sharifian-Dorche A., Mohammadi P., Nomovi M., Mowla A. Vaccine-Induced Immune Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis Post COVID-19 Vaccination; A Systematic Review. J. Neurol. Sci. 2021;428:117607. doi: 10.1016/j.jns.2021.117607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2021.117607</ArticleId><ArticleId IdType="pmc">PMC8330139</ArticleId><ArticleId IdType="pubmed">34365148</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H., Kakiuchi S., Rikitake J., Matsuba H., Sekinada D., Kozuki Y., Iwata N. Immune Thrombocytopenia Associated with Pfizer-BioNTech&#x2019;s BNT162b2 MRNA COVID-19 Vaccine. IDCases. 2021;25:e01245. doi: 10.1016/j.idcr.2021.e01245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idcr.2021.e01245</ArticleId><ArticleId IdType="pmc">PMC8336989</ArticleId><ArticleId IdType="pubmed">34381692</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharjee S., Banerjee M. Immune Thrombocytopenia Secondary to COVID-19: A Systematic Review. SN Compr. Clin. Med. 2020;2:2048. doi: 10.1007/s42399-020-00521-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42399-020-00521-8</ArticleId><ArticleId IdType="pmc">PMC7501509</ArticleId><ArticleId IdType="pubmed">32984764</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah S.R.A., Dolkar S., Mathew J., Vishnu P. COVID-19 Vaccination Associated Severe Immune Thrombocytopenia. Exp. Hematol. Oncol. 2021;10:42. doi: 10.1186/s40164-021-00235-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40164-021-00235-0</ArticleId><ArticleId IdType="pmc">PMC8280588</ArticleId><ArticleId IdType="pubmed">34266487</ArticleId></ArticleIdList></Reference><Reference><Citation>Fueyo-Rodriguez O., Valente-Acosta B., Jimenez-Soto R., Neme-Yunes Y., Incl&#xe1;n-Alarc&#xf3;n S.I., Trejo-Gonzalez R., Garc&#xed;a-Salcido M.&#xc1;. Secondary Immune Thrombocytopenia Supposedly Attributable to COVID-19 Vaccination. BMJ Case Rep. 2021;14:e242220. doi: 10.1136/bcr-2021-242220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2021-242220</ArticleId><ArticleId IdType="pmc">PMC8169472</ArticleId><ArticleId IdType="pubmed">34059544</ArticleId></ArticleIdList></Reference><Reference><Citation>Candelli M., Rossi E., Valletta F., de Stefano V., Franceschi F. Immune Thrombocytopenic Purpura after SARS-CoV-2 Vaccine. Br. J. Haematol. 2021;194:547&#x2013;549. doi: 10.1111/bjh.17508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17508</ArticleId><ArticleId IdType="pmc">PMC8239819</ArticleId><ArticleId IdType="pubmed">33934330</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry R.J., Tamborska A., Singh B., Craven B., Marigold R., Arthur-Farraj P., Yeo J.M., Zhang L., Hassan-Smith G., Jones M., et al. Cerebral Venous Thrombosis after Vaccination against COVID-19 in the UK: A Multicentre Cohort Study. Lancet. 2021;398:1147&#x2013;1156. doi: 10.1016/S0140-6736(21)01608-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01608-1</ArticleId><ArticleId IdType="pmc">PMC8346241</ArticleId><ArticleId IdType="pubmed">34370972</ArticleId></ArticleIdList></Reference><Reference><Citation>Scully M., Singh D., Lown R., Poles A., Solomon T., Levi M., Goldblatt D., Kotoucek P., Thomas W., Lester W. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 NCoV-19 Vaccination. N. Engl. J. Med. 2021;384:2202&#x2013;2211. doi: 10.1056/NEJMoa2105385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105385</ArticleId><ArticleId IdType="pmc">PMC8112532</ArticleId><ArticleId IdType="pubmed">33861525</ArticleId></ArticleIdList></Reference><Reference><Citation>McCrae K.R. Thrombotic Thrombocytopenia Due to SARS-CoV-2 Vaccination. Clevel. Clin. J. Med. 2021 doi: 10.3949/ccjm.88a.ccc078.</Citation><ArticleIdList><ArticleId IdType="doi">10.3949/ccjm.88a.ccc078</ArticleId><ArticleId IdType="pubmed">33958344</ArticleId></ArticleIdList></Reference><Reference><Citation>Welsh K.J., Baumblatt J., Chege W., Goud R., Nair N. Thrombocytopenia Including Immune Thrombocytopenia after Receipt of MRNA COVID-19 Vaccines Reported to the Vaccine Adverse Event Reporting System (VAERS) Vaccine. 2021;39:3329&#x2013;3332. doi: 10.1016/j.vaccine.2021.04.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.04.054</ArticleId><ArticleId IdType="pmc">PMC8086806</ArticleId><ArticleId IdType="pubmed">34006408</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E.J., Cines D.B., Gernsheimer T., Kessler C., Michel M., Tarantino M.D., Semple J.W., Arnold D.M., Godeau B., Lambert M.P., et al. Thrombocytopenia Following Pfizer and Moderna SARS-CoV-2 Vaccination. Am. J. Hematol. 2021;96:534&#x2013;537. doi: 10.1002/ajh.26132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26132</ArticleId><ArticleId IdType="pmc">PMC8014568</ArticleId><ArticleId IdType="pubmed">33606296</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarawneh O., Tarawneh H. Immune Thrombocytopenia in a 22-Year-Old Post Covid-19 Vaccine. Am. J. Hematol. 2021;96:E133&#x2013;E134. doi: 10.1002/ajh.26106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26106</ArticleId><ArticleId IdType="pmc">PMC8014773</ArticleId><ArticleId IdType="pubmed">33476455</ArticleId></ArticleIdList></Reference><Reference><Citation>Toom S., Wolf B., Avula A., Peeke S., Becker K. Familial Thrombocytopenia Flare-up Following the First Dose of MRNA-1273 Covid-19 Vaccine. Am. J. Hematol. 2021;96:E134&#x2013;E135. doi: 10.1002/ajh.26128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26128</ArticleId><ArticleId IdType="pmc">PMC8014325</ArticleId><ArticleId IdType="pubmed">33580970</ArticleId></ArticleIdList></Reference><Reference><Citation>Shazley O., Alshazley M. A COVID-Positive 52-Year-Old Man Presented with Venous Thromboembolism and Disseminated Intravascular Coagulation Following Johnson &amp; Johnson Vaccination: A Case-Study. Cureus. 2021;13:e16383. doi: 10.7759/CUREUS.16383.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/CUREUS.16383</ArticleId><ArticleId IdType="pmc">PMC8362796</ArticleId><ArticleId IdType="pubmed">34408937</ArticleId></ArticleIdList></Reference><Reference><Citation>Greinacher A., Thiele T., Warkentin T.E., Weisser K., Kyrle P.A., Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 NCoV-19 Vaccination. N. Engl. J. Med. 2021;384:2092&#x2013;2101. doi: 10.1056/NEJMoa2104840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2104840</ArticleId><ArticleId IdType="pmc">PMC8095372</ArticleId><ArticleId IdType="pubmed">33835769</ArticleId></ArticleIdList></Reference><Reference><Citation>Gambichler T., Boms S., Susok L., Dickel H., Finis C., Abu Rached N., Barras M., St&#xfc;cker M., Kasakovski D. Cutaneous Findings Following COVID-19 Vaccination: Review of World Literature and Own Experience. J. Eur. Acad. Dermatol. Venereol. 2022;36:172&#x2013;180. doi: 10.1111/jdv.17744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.17744</ArticleId><ArticleId IdType="pmc">PMC8656409</ArticleId><ArticleId IdType="pubmed">34661927</ArticleId></ArticleIdList></Reference><Reference><Citation>Catal&#xe0; A., Mu&#xf1;oz-Santos C., Galv&#xe1;n-Casas C., Roncero Riesco M., Revilla Nebreda D., Sol&#xe1;-Truyols A., Giavedoni P., Llamas-Velasco M., Gonz&#xe1;lez-Cruz C., Cubir&#xf3; X., et al. Cutaneous Reactions after SARS-CoV-2 Vaccination: A Cross-Sectional Spanish Nationwide Study of 405 Cases. Br. J. Dermatol. 2022;186:142&#x2013;152. doi: 10.1111/bjd.20639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.20639</ArticleId><ArticleId IdType="pmc">PMC8444756</ArticleId><ArticleId IdType="pubmed">34254291</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita S., Katsuki N.E., Tago M., Yamashita S.I. Dyspnea and Wheezing as the Earliest Manifestations of Severe Fever with Thrombocytopenia Syndrome: The First Case Report. Intern. Med. 2019;58:2731. doi: 10.2169/internalmedicine.2660-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.2660-19</ArticleId><ArticleId IdType="pmc">PMC6794175</ArticleId><ArticleId IdType="pubmed">31178498</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X.J., Liang M.F., Zhang S.Y., Liu Y., Li J.D., Sun Y.L., Zhang L., Zhang Q.F., Popov V.L., Li C., et al. Fever with Thrombocytopenia Associated with a Novel Bunyavirus in China. N. Engl. J. Med. 2011;364:81&#x2013;84. doi: 10.1056/NEJMoa1010095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1010095</ArticleId><ArticleId IdType="pmc">PMC3113718</ArticleId><ArticleId IdType="pubmed">21410387</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., He B., Huang S.Y., Wei F., Zhu X.Q. Severe Fever with Thrombocytopenia Syndrome, an Emerging Tick-Borne Zoonosis. Lancet Infect. Dis. 2014;14:763&#x2013;772. doi: 10.1016/S1473-3099(14)70718-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(14)70718-2</ArticleId><ArticleId IdType="pubmed">24837566</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y., Wu H., Gao J., Zhou X., Zhu R., Zhang C., Bai H., Abdullah A.S., Pan H. Two Confirmed Cases of Severe Fever with Thrombocytopenia Syndrome with Pneumonia: Implication for a Family Cluster in East China. BMC Infect. Dis. 2017;17:537. doi: 10.1186/s12879-017-2645-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-017-2645-9</ArticleId><ArticleId IdType="pmc">PMC5541732</ArticleId><ArticleId IdType="pubmed">28774267</ArticleId></ArticleIdList></Reference><Reference><Citation>Frith J., Watson S., Maggs P.H.B.B., Newton J.L. Cognitive Symptoms Are Common in Immune Thrombocytopenia and Associate with Autonomic Symptom Burden. Eur. J. Haematol. 2012;88:224&#x2013;228. doi: 10.1111/j.1600-0609.2011.01730.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0609.2011.01730.x</ArticleId><ArticleId IdType="pubmed">22044734</ArticleId></ArticleIdList></Reference><Reference><Citation>Awan H.A., Najmuddin Diwan M., Aamir A., Ali M., di Giannantonio M., Ullah I., Shoib S., de Berardis D. SARS-CoV-2 and the Brain: What Do We Know about the Causality of &#x2019;Cognitive COVID? J. Clin. Med. 2021;10:3441. doi: 10.3390/jcm10153441.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10153441</ArticleId><ArticleId IdType="pmc">PMC8347421</ArticleId><ArticleId IdType="pubmed">34362224</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency  AstraZeneca&#x2019;s COVID-19 Vaccine: EMA Finds Possible Link to Very Rare Cases of Unusual Blood Clots with Low Blood Platelets.  [(accessed on 13 May 2022)].  Available online:  https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood.</Citation></Reference><Reference><Citation>Douxfils J., Favresse J., Dogn&#xe9; J.M., Lecompte T., Susen S., Cordonnier C., Lebreton A., Gosselin R., Si&#xe9; P., Pernod G., et al. Hypotheses behind the Very Rare Cases of Thrombosis with Thrombocytopenia Syndrome after SARS-CoV-2 Vaccination. Thromb. Res. 2021;203:163. doi: 10.1016/j.thromres.2021.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2021.05.010</ArticleId><ArticleId IdType="pmc">PMC8123522</ArticleId><ArticleId IdType="pubmed">34029848</ArticleId></ArticleIdList></Reference><Reference><Citation>Potteg&#xe5;rd A., Lund L.C., Karlstad &#xd8;., Dahl J., Andersen M., Hallas J., Lidegaard &#xd8;., Tapia G., Gulseth H.L., Ruiz P.L.D., et al. Arterial Events, Venous Thromboembolism, Thrombocytopenia, and Bleeding after Vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: Population Based Cohort Study. BMJ. 2021;373:n1114. doi: 10.1136/bmj.n1114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1114</ArticleId><ArticleId IdType="pmc">PMC8097496</ArticleId><ArticleId IdType="pubmed">33952445</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen T.N., Siegler J.E., Yaghi S., Vigilante N., Abdalkader M., Coutinho J.M., Abdul Khalek F. Cerebral Vein Thrombosis with Vaccine-Induced Immune Thrombotic Thrombocytopenia. Stroke. 2021;52:3045&#x2013;3053. doi: 10.1161/STROKEAHA.121.035613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.121.035613</ArticleId><ArticleId IdType="pmc">PMC8378439</ArticleId><ArticleId IdType="pubmed">34304601</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Nieto D., Haemmerle J., Fern&#xe1;ndez Escribano M. Skin Manifestations of the BNT162b2 MRNA COVID-19 Vaccine in Healthcare Workers. &#x201c;COVID-Arm&#x201d;: A Clinical and Histological Characterization. J. Eur. Acad. Dermatol. Venereol. 2021;35:e425&#x2013;e427. doi: 10.1111/jdv.17250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.17250</ArticleId><ArticleId IdType="pmc">PMC8251500</ArticleId><ArticleId IdType="pubmed">33783873</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinaldi M., Perricone C., Ortega-Hernandez O.D., Perricone R., Shoenfeld Y. Immune Thrombocytopaenic Purpura: An Autoimmune Cross-Link between Infections and Vaccines. Lupus. 2014;23:554&#x2013;567. doi: 10.1177/0961203313499959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313499959</ArticleId><ArticleId IdType="pubmed">24763539</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamiel U., Kventsel I., Youngster I. Recurrent Immune Thrombocytopenia After Influenza Vaccination: A Case Report. Pediatrics. 2016;138:e20160124. doi: 10.1542/peds.2016-0124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2016-0124</ArticleId><ArticleId IdType="pubmed">27940665</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantadakis E., Farmaki E., Thomaidis S., Tsalkidis A., Chatzimichael A. A Case of Immune Thrombocytopenic Purpura after Influenza Vaccination: Consequence or Coincidence? J. Pediatric Hematol. Oncol. 2010;32:e227&#x2013;e229. doi: 10.1097/MPH.0b013e3181e33fe0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPH.0b013e3181e33fe0</ArticleId><ArticleId IdType="pubmed">20539239</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier D.A., Ferreira I.A.T.M., Kotagiri P., Datir R.P., Lim E.Y., Touizer E., Meng B., Abdullahi A., Baker S., Dougan G., et al. Age-Related Immune Response Heterogeneity to SARS-CoV-2 Vaccine BNT162b2. Nature. 2021;596:417&#x2013;422. doi: 10.1038/s41586-021-03739-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03739-1</ArticleId><ArticleId IdType="pmc">PMC8373615</ArticleId><ArticleId IdType="pubmed">34192737</ArticleId></ArticleIdList></Reference><Reference><Citation>Jasaraj R.B., Shrestha D.B., Gaire S., Kassem M. Immune Thrombocytopenic Purpura Following Pfizer-BioNTech COVID-19 Vaccine in an Elderly Female. Cureus. 2021;13:e16871. doi: 10.7759/cureus.16871.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.16871</ArticleId><ArticleId IdType="pmc">PMC8414938</ArticleId><ArticleId IdType="pubmed">34513446</ArticleId></ArticleIdList></Reference><Reference><Citation>Nachtigall I., Bonsignore M., Hohenstein S., Bollmann A., G&#xfc;nther R., Kodde C., Englisch M., Ahmad-Nejad P., Schr&#xf6;der A., Glenz C., et al. Effect of Gender, Age and Vaccine on Reactogenicity and Incapacity to Work after COVID-19 Vaccination: A Survey among Health Care Workers. BMC Infect. Dis. 2022;22:291. doi: 10.1186/s12879-022-07284-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07284-8</ArticleId><ArticleId IdType="pmc">PMC8960217</ArticleId><ArticleId IdType="pubmed">35346089</ArticleId></ArticleIdList></Reference><Reference><Citation>Anjorin A.A., Odetokun I.A., Nyandwi J.B., Elnadi H., Awiagah K.S., Eyedo J., Abioye A.I., Gachara G., Maisara A.M., Razouqi Y., et al. Public Health Surveillance for Adverse Events Following COVID-19 Vaccination in Africa. Vaccines. 2022;10:546. doi: 10.3390/vaccines10040546.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10040546</ArticleId><ArticleId IdType="pmc">PMC9032114</ArticleId><ArticleId IdType="pubmed">35455295</ArticleId></ArticleIdList></Reference><Reference><Citation>Green M.S., Peer V., Magid A., Hagani N., Anis E., Nitzan D. Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine. Vaccines. 2022;10:233. doi: 10.3390/vaccines10020233.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10020233</ArticleId><ArticleId IdType="pmc">PMC8875740</ArticleId><ArticleId IdType="pubmed">35214694</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Z., van der Ploeg K., Chakraborty S., Arunachalam P., Mori D., Jacobson K., Bonilla H., Parsonnet J., Andrews J., Hedlin H., et al. Early Immune Responses Have Long-Term Associations with Clinical, Virologic, and Immunologic Outcomes in Patients with COVID-19. Res. Sq. 2022, preprint.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/RS.3.RS-847082/V1</ArticleId></ArticleIdList></Reference><Reference><Citation>Malayala S.V., Mohan G., Vasireddy D., Atluri P. Purpuric Rash and Thrombocytopenia After the MRNA-1273 (Moderna) COVID-19 Vaccine. Cureus. 2021;13:e14099. doi: 10.7759/cureus.14099.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.14099</ArticleId><ArticleId IdType="pmc">PMC7996471</ArticleId><ArticleId IdType="pubmed">33786251</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong J., Cuevas-Castillo F., Nassar M., Lei C.M., Idrees Z., Fix W.C., Halverstam C., Mir A., Elbendary A., Mathew A. Bullous Drug Eruption after Second Dose of MRNA-1273 (Moderna) COVID-19 Vaccine: Case Report. J. Infect. Public Health. 2021;14:1392&#x2013;1394. doi: 10.1016/j.jiph.2021.06.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2021.06.021</ArticleId><ArticleId IdType="pmc">PMC8264280</ArticleId><ArticleId IdType="pubmed">34294590</ArticleId></ArticleIdList></Reference><Reference><Citation>Meo S.A., Bukhari I.A., Akram J., Meo A.S., Klonoff D.C. COVID-19 Vaccines: Comparison of Biological, Pharmacological Characteristics and Adverse Effects of Pfizer/BioNTech and Moderna Vaccines. Eur. Rev. Med. Pharmacol. Sci. 2021;25:1663&#x2013;1679. doi: 10.26355/EURREV_202102_24877.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/EURREV_202102_24877</ArticleId><ArticleId IdType="pubmed">33629336</ArticleId></ArticleIdList></Reference><Reference><Citation>Neylon A.J., Saunders P.W.G., Howard M.R., Proctor S.J., Taylor P.R.A. Clinically Significant Newly Presenting Autoimmune Thrombocytopenic Purpura in Adults: A Prospective Study of a Population-Based Cohort of 245 Patients. Br. J. Haematol. 2003;122:966&#x2013;974. doi: 10.1046/j.1365-2141.2003.04547.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2141.2003.04547.x</ArticleId><ArticleId IdType="pubmed">12956768</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahamson P.E., Hall S.A., Feudjo-Tepie M., Mitrani-Gold F.S., Logie J. The Incidence of Idiopathic Thrombocytopenic Purpura among Adults: A Population-Based Study and Literature Review. Eur. J. Haematol. 2009;83:83&#x2013;89. doi: 10.1111/j.1600-0609.2009.01247.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0609.2009.01247.x</ArticleId><ArticleId IdType="pubmed">19245532</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarpatwari A., Bennett D., Logie J.W., Shukla A., Beach K.J., Newland A.C., Sanderson S., Provan D. Thromboembolic Events among Adult Patients with Primary Immune Thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica. 2010;95:1167&#x2013;1175. doi: 10.3324/haematol.2009.018390.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2009.018390</ArticleId><ArticleId IdType="pmc">PMC2895042</ArticleId><ArticleId IdType="pubmed">20145266</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Nardi M.A., Borkowsky W., Li Z., Karpatkin S. Role of Molecular Mimicry of Hepatitis C Virus Protein with Platelet GPIIIa in Hepatitis C-Related Immunologic Thrombocytopenia. Blood. 2009;113:4086&#x2013;4093. doi: 10.1182/blood-2008-09-181073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2008-09-181073</ArticleId><ArticleId IdType="pmc">PMC2673130</ArticleId><ArticleId IdType="pubmed">19023115</ArticleId></ArticleIdList></Reference><Reference><Citation>Aster R.H. Molecular Mimicry and Immune Thrombocytopenia. Blood. 2009;113:3887&#x2013;3888. doi: 10.1182/blood-2008-12-193664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2008-12-193664</ArticleId><ArticleId IdType="pmc">PMC2673118</ArticleId><ArticleId IdType="pubmed">19389889</ArticleId></ArticleIdList></Reference><Reference><Citation>Au L., Fendler A., Shepherd S.T.C., Rzeniewicz K., Cerrone M., Byrne F., Carlyle E., Edmonds K., del Rosario L., Shon J., et al. Cytokine Release Syndrome in a Patient with Colorectal Cancer after Vaccination with BNT162b2. Nat. Med. 2021;27:1362&#x2013;1366. doi: 10.1038/s41591-021-01387-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01387-6</ArticleId><ArticleId IdType="pmc">PMC8363501</ArticleId><ArticleId IdType="pubmed">34040262</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihtesham A., Maqbool S., Nadeem M., Janjua M.B.A., Sundus O., Naqqash A.B., Mohamed W.I., Haider S.T., Ahmad M., Mustafa M.A.T., et al. Helicobacter pylori induced Immune Thrombocytopenic Purpura and perspective role of Helicobacter pylori eradication therapy for treating Immune Thrombocytopenic Purpura. AIMS Microbiol. 2021;7:284&#x2013;303. doi: 10.3934/microbiol.2021018.</Citation><ArticleIdList><ArticleId IdType="doi">10.3934/microbiol.2021018</ArticleId><ArticleId IdType="pmc">PMC8500795</ArticleId><ArticleId IdType="pubmed">34708173</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogagnolo A., Campo G.C., Mari M., Pompei G., Pavasini R., Volta C.A., Spadaro S. The Underestimated Role of Platelets in Severe Infection a Narrative Review. Cells. 2022;11:424. doi: 10.3390/cells11030424.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11030424</ArticleId><ArticleId IdType="pmc">PMC8834344</ArticleId><ArticleId IdType="pubmed">35159235</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>